Skip to main content
Log in

Antimetastatic effects of razoxane in a rat osteosarcoma model

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

The cytostatic and antimetastatic activities of 1,2-di(3,5-dioxopiperazin-1-yl) propane (ICRF-159, razoxane) were studied in a transplantable, slowly growing osteosarcoma in Sprague-Dawley rats. This tumor model is characterized by osteoid formation and spontaneous metastasization to lungs, kidneys and lymph nodes. Razoxane given intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation (30 mg/kg or 10 mg/kg per day) resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor.

Early treatment with razoxane (30 mg/kg i.p. from day −2 to + 14) showed a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation). Whereas 59·9 per cent of the total sectional area of the lungs in the control animals was covered by osteosarcoma metastases, only 3·4 per cent and 26·1 per cent respectively was affected in the early and late razoxane treatment groups. Toxic side-effects of these treatment schedules were reversible diffuse alopecia, but no retardation of body weight gain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Boggust, W. A., and O'Connel, S., 1980, Changes in cells induced by drugs inhibiting experimental tumour metastasis in mice, by polyamines and by radiation. Excerpta Medica International Congress Series, 484, 374–386.

    Google Scholar 

  2. Boggust, W. A., O'Connell, S., Carroll, R., and Wilson, P., 1980, Inhibition of metastasic tumour development in WHT/HT mice by Putrescine, Spermidine and Spermine administration. IRCS Medical Science: Cancer, 8, 597–598.

    Google Scholar 

  3. Creighton, A. M., Hellmann, K., and Whitecross, S., 1969, Antitumor activity in a series of bisdioxopiperazines. Nature, 222, 384.

    Google Scholar 

  4. Gilbert, J. M., Hellmann, K., Evans, M., Cassell, P. G., Stoodley, B., Ellis, H., and Wastell, C., 1982, Adjuvant oral razoxane (ICRF-159) in resectable colorectal cancer. Cancer Chemotherapy and Pharmacology, 8, 293–299.

    Google Scholar 

  5. Hellmann, K., 1984, Razoxane. Clinical Chemotherapy, Vol. III, Antineoplastic Chemotherapy, edited by H. P. Kuemmerle (New York: Thieme-Stratton), pp. 275–282.

    Google Scholar 

  6. Herman, E. U., Witiak, D. T., Hellmann, K., and Waravdekar, V. S., 1982, Biological properties of ICRF-159 and related Bis(dioxopiperazine) compounds. Advances in Pharmacology and Chemotherapy, 19, 249–290.

    Google Scholar 

  7. Kadmon, D., Heston, W. D., and Fair, W. R., 1981, Effect of surgery and adjuvant chemotherapy on the R3327 MAT-LY LU tumor. Prostate, 2, 299–307.

    Google Scholar 

  8. Salsbury, A. J., Burrage, K., and Hellmann, K., 1970, Inhibition of metastatic spread by ICRF 159: Selective deletion of a malignant characteristic. British Medical Journal, 4, 344–346.

    Google Scholar 

  9. Salsbury, A. J., Burrage, K., and Hellmann, K., 1974, Histological analysis of the antimetastatic effect of (−)-1,2-Bis(3,5-dioxopiperazine-1-yl) propane. Cancer Research, 34, 843–849.

    Google Scholar 

  10. Skolnik, G., Bagge, U., and Hilgard, P., 1985,The effect of a primary tumour and its metastases on the lodgement of circulating tumour cells. Treatment of Metastasis: Problems and Prospects, edited by K. Hellmann and S. A. Eccles (London, Philadelphia: Taylor & Francis), pp. 219–222.

    Google Scholar 

  11. Weber, E., 1982, (Hrsg.) Statistische Auswertung biomedizinischer Daten—Teil II, Survival. Deutsches Krebsforschungszentrum, Heidelberg.

    Google Scholar 

  12. Wingen, F., Schmahl, D., Berger, M. R., and Spring, H., 1984, Intraosseously transplantable osteosarcoma with regularly disseminating pulmonary metastases in rats. Cancer Letters, 23, 201–211.

    Google Scholar 

  13. Wingen, F., and Schmahl, D., 1985,A transplantable osteosarcoma in rats with regular occurrence of lung metastases as a model for chemotherapy. Treatment of Metastasis: Problems and Prospects, edited by K. Hellmannand S. A. Eccles (London, Philadelphia: Taylor & Francis), pp. 107–111.

    Google Scholar 

  14. Wingen, F., and Weber, E., 1987, Changing metastatic patterns of transplantable rat osteosarcoma. Clinical and Fxperimental Metastasis, 5, 17–26.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wingen, F., Spring, H. & Schmähl, D. Antimetastatic effects of razoxane in a rat osteosarcoma model. Clin Exp Metast 5, 9–16 (1987). https://doi.org/10.1007/BF00116621

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00116621

Keywords

Navigation